Ocular Surgery News U.S. Edition, July 25, 2017
Darrell E. White, MD
As we head into the summer months, I thought it would be helpful to take the pulse of our dry eye world and report on the state of the state, if you will. In part 1 I reviewed how we are diagnosing dry eye in our clinics — and learned that the news cycle does not respect the editorial/creative process when RPS sold InflammaDry while my piece was in turnaround. Let us now examine the state of dry eye disease treatment.
As a group, doctors who treat DED have become much more sophisticated in how they approach care. An ophthalmologist or optometrist makes an effort to confirm that it is, indeed, DED that is producing the majority of a patient’s symptoms. Once this is accomplished, we then determine if the primary type of the dry eye is aqueous deficient or evaporative. From this starting point there are, at the moment, two major treatment pathways: address the health of meibomian glands and address the presence of inflammation.